Pemetrexed in malignant pleural mesothelioma and the clinical outcome
Conclusions: Pemetrexed is beneficial for selected patients, but it has not changed the outcome of the whole MPM population as much as perhaps anticipated. Patient groups with various treatments or symptomatic care only reached survival results comparable to those reported in chemotherapy trials, thus emphasizing the need for better subtyping of mesothelioma and individualising the treatment. (Source: The Clinical Respiratory Journal)